Skip to main content

The Cleone Peterson Eccles Alumni House at the University of Utah

alumnihouse

3rd Annual Translational Hypertension Symposium & Early-Stage Investigator Workshop

October 10-11, 2019

High blood pressure affects more than a billion people worldwide and remains a leading modifiable cause of heart disease and health disparities. New in- and out-of-office blood pressure measurement devices and strategies are being tested to more efficiently and accurately screen and diagnose hypertension for people from all communities and backgrounds. Antihypertensive medications are being combined in news ways to increase effectiveness, limit side effects, while maximizing patient acceptance and adherence. Together, the ultimate goal is more accurate diagnosis and more effective and durable blood pressure control and cardiovascular disease risk reduction for all communities.

The Symposium is specifically designed to be an intimate full-day experience allowing significant time for participants to meet and mingle with experts and speakers. Come take advantage of this unique opportunity to interact with people you've heard about but may have never met.

The Early-Stage Investigator (ESI) Workshop takes place the day after the symposium and is a full day, intensive mentoring session where ESIs learn how to access and design hypertension-related analyses using the Jackson Heart Study (JHS) and The Coronary Artery Risk Development in Young Adults (CARDIA) study data and write clear manuscript proposals. This year, there will be a focus on using the ambulatory blood pressure monitoring data in these two chohorts. The objective is to teach ESIs about the manuscript proposal process, data access, and BP-related research methods for the JHS and CARDIA study. Senior JHS and CARDIA investigators will provide one-on-one feedback, and facilitate group discussions to enable ESIs to use and access the JHS and CARDIA data. Applications for the ESI Workshop are due Thursday, August 1st and awardees will be notified no later than August 16th, 2019.

 The 2019 Symposium addresses these topics and more, with confirmed speakers:

olugbengaogedegbe.jpg Keynote speaker Gbenga Ogedegbe, MD, MPH, from New York University, who will present the results of the FAITH study
nataliebellow.jpg Natalie Bello, MD, MPH, from Columbia University, will discuss out-of-office BP monitoring in pregnancy
picdavedixon.jpg Dave L. Dixon, PharmD, FACC, from Virginia Commonwealth University, will discuss team-based apporaches to imporve high blood pressure outcomes 
marchuffman.jpg Mark D. Huffman, MD, MPH, from Northwestern, will discuss use of low-dose combinations of antihypertensive medications
andrew_moran2.jpg Andrew Moran, MD, MPH, from Columbia University, will discuss The Global Hypertension Control Mission of Resolve to Save Lives
schwartzjoseph.jpeg Joseph Schwartz, PhD, from Columbia University, will discuss the state of the art of ambulatory blood pressure monitoring and out-of-office blood pressure phenotype.
wrightjacksondr.jpg Jackson T. Wright, MD, PhD, FACP, from Case Western Reserve University, will discuss the future of hypertension management in underrepresented groups
yuchiroyano.jpg Yuichiro Yano, MD, PhD, from Duke University, will discuss the current challenges in out-of-office blood pressure monitoring

 

cme-logo.jpg   

Accreditation: The University Of Utah School Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit: The University of Utah School of Medicine designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nondiscrimination and Disability Accommodation Statement: The University of Utah does not exclude, deny benefits to or otherwise discriminate against any person on the basis of race, color, national origin, sex, disability, age, veteran’s status, religion, gender identity/expression, genetic information, or sexual orientation in admission to or participation in its programs and activities.  Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice.  Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA, Title IX/Section 504/ADA Coordinator, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).

Speaker and Planning Committee Disclosure Summary:

The University Of Utah School Of Medicine Continuing Medical Education Office meets the ACCME expectations regarding the identification and resolution of conflicts of interest that arise from financial relationships with commercial interests.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership or advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. We consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Everyone in control of content, including all speakers and planners are expected to disclose any relevant financial relationships in any amount within the past 12 months. Speakers are also expected to openly disclose intent to discuss any off-label, experimental, or investigational use of drugs, devices, or equipment in their presentations.

No one in The University of Utah Continuing Medical Education Office in control of content for the course has any relevant financial relationship with commercial products or services discussed during this conference.

Name

Role in Activity

Conflicts?

Relevant Financial Relationships

Kristi Reynolds

Moderator

Yes

Merck & Co; research support through my institution, Novartis; research support through my institution, Vital Strategies/Resolve to Save Lives; research support through my institution.

William C. Cushman

Moderator

No

 

Joseph Miner

Speaker

No

 

Kola Okuyemi

Moderator

No

 

Jordana Cohen

Planner, Moderator

No

 

Joseph Schwartz

Speaker

No

 

Yuichiro Yano

Speaker

No

 

Olugbenga Ogedegbe

Speaker

No

 

Adam Bress

Planner

No

 

Dave Dixon

Speaker

No

 

Jackson T Wright Jr

Speaker

No

 

Mark Huffman

Speaker

Yes

Research grant from One Brave Idea, which is a joint venture between American Heart Association, Verily, AstraZeneca; Secondary appointment at The George Institute for Global Health whose subsidiary, George Medicines, has a patent, license and investors for aspirin, statin, and blood pressure lowering therapy.  I am not directly involved with these trials and do not have direct financial relationship with these products. American Medical Association, salary for serving as associate editor for JAMA Cardiology. World Heart Federation, contract funding to serve as the senior program advisor for its Emerging Leaders program, which has been funded by Boehringer Ingelheim and Novartis.

Natalie A Bello

Speaker

No

 

Andrew E Moran

Speaker

No

 

Santiago Isaza

Planner

No

 

April Mohanty

Planner, Speaker, Moderator

No